Welcome back to The Week in Weed, your Friday look at what’s happening in the world of legalized marijuana.

COVID-19 continues to dominate the news – no surprise there.  Whether it’s federal relief or state legalization roadblocks, the virus is everywhere.  But there is some other news: the IRS seems likely to increase auditing of marijuana businesses, and Epidiolex has
Continue Reading The Week in Weed: April 10, 2020

This is Washington, and we do like to speak in initials.  A plain English translation of the title of this piece would read “FDA ‘places FDA-approved drugs that contain CBD derived from cannabis and no more than 0.1 percent tetrahydrocannabinols in Schedule V.’”  DEA Final Order, Docket No. DEA-486 Schedule V drugs include cough medicine with codeine and many pain relievers that still require a prescription.  So, really what this order does is allow doctors in the US legally to prescribe the recently approved epilepsy drug, Epidiolex, and allows pharmacies, rather than marijuana dispensaries, legally to sell the drug.
Continue Reading FDA: .1% CBD OK

Welcome back to The Week in Weed, your Friday look at what’s happening in the world of legalized marijuana.

At the risk of turning this into the “Week in Oklahoma Weed,” here’s the latest on what happening in the Sooner State.

A group that wants
Continue Reading The Week in Weed: August 17, 2018